Inclera is led by Charles McOsker, Ph.D., and supported by Kaushik Ghosal, Ph.D., and Angela Corona, Ph.D.  Our team brings extensive experience guiding business development strategy for early stage biotech and pharmaceuticals companies, leveraging their expertise to accelerate academic research towards commercialization with our partners.


Charles McOsker, Ph.D., Senior Vice President

Inclera is led by Charles McOsker, Ph.D., who brings over 30 years of experience in the pharmaceutical and biotechnology industries, and an extensive background in the management of multi-functional teams in drug discovery and development. 

Before joining Inclera in 2017, Dr. McOsker founded Airway Therapeutics, a biotechnology company created to develop promising therapeutics arising from within the pulmonary research program of Cincinnati Children’s Hospital Medical Center. At Airway Therapeutics, Dr. McOsker successfully managed the early stages of the company’s technology development and fundraising. Previously, Dr. McOsker served as Director of Business Development for the Drug Discovery Center at the University of Cincinnati where he was responsible for negotiating agreements with a potential value to the University of over $30 million. Dr. McOsker began his career at Procter & Gamble Pharmaceuticals. Over the course of 23 years, he held numerous management positions in drug discovery and development and was responsible for teams that discovered two products that successfully entered late-stage clinical development. 

Dr. McOsker received his undergraduate degree in chemistry at Hope College in Michigan and his PhD in biochemistry and molecular biology at Cornell University. 



Inclera's business development team works to develop and execute on commercialization plans for our portfolio technologies, manage relationships with our network of subject-matter experts, and cultivate development and funding partnerships with investors, government agencies, and academic institutions.

Kaushik Ghosal, Ph.D.

Dr. Ghosal brings extensive drug development expertise in neuroscience, stem cells, and cancer therapeutics to Inclera.  He is currently a Director of Business Development at BioMotiv, and the Director of Research and Development for ReXceptor Inc., a biotech start-up focused on neurological disorders. He has authored several journal and review articles and serves on the editorial boards of multiple scientific journals as well as a grant reviewer for Agence Nationale de la Recherche, France and SBIR/STTR for the NIH. 

Dr. Ghosal completed his Ph.D. in Neuroscience at Miami University and holds a M.S. in Biotechnology from the Indian Institute of Technology, Bombay.


Angela W. Corona, Ph.D.

Dr. Corona brings significant expertise in sourcing, applying, and negotiating for funding for early-stage biotech companies to Inclera. She is currently a Director of Business Development at BioMotiv, and was previously a Neuroscientist in the Alzheimer’s Disease Research Laboratory at Case Western Reserve University in Cleveland, OH, where she was awarded a Ruth L. Kirschstein National Research Service Award from the NIH for her work. She has published her work in more than a dozen primary research and review articles.

Dr. Corona completed her Ph.D. in Neuroscience at the Ohio State University and holds a B.S. in Biochemistry from Binghamton University.